customise ic Parameters of Envarsus XR C max c (ng/mL) T max d (hr) AUC 24 c (ng•hr/mL) C 24 h (ng/mL) Healthy Subjects a (n=19) 2 mg 2 mg Day 1 Day 10 11.9 3.8 8.3 2.9 14.0 [6 - 28] 8.0 [1.0-12.0] 50 14 140 50 1.8 0.6 4.6 1.7 Adult Kidney a De novo e (n=21) 11.8 mg f 10 mg 9.5 mg Day 1 Day 7 Day 14 11.8 7.2 25.1 16.3 27.1 13.4 8.0 [4-24] 6.0 [2-12] 4.0 [1-8] 138 80 335 129 371 104 5.2 2.7 9.9 4.4 11.4 4.1 j Adult Kidney a De novo (n=10) 15.5 mg g 11.4 mg 11.1 mg Day 1 Day 14 Day 28 33.6 21.8 31.1 14.6 35.9 18.7 6.0 [4-24] 4.0 [1-18] 4.0 [1-14] 377 257 376 140 396 150 11.0 6.1 9.1 3.0 10.5 3.2 Adult Kidney a (≥ 6 months post- transplant) (n=47) 5.3 mg Day 7 i 13.5 4.8 6.0 [1 - 16] 216 63 7.0 2.3 j Adult African- American Kidney k (≥ 6 months post-transplant) (n=46) 7.8 mg Day 7 i 18.4 7.2 5.0 [1 - 16] 272 97 7.8 2.9 j In adult kidney transplant patients ≥ 6 months post-transplant switched to Envarsus XR at 67% to 80% of the daily dose of tacrolimus immediate-release capsules pictures
Photo :ic Parameters of Envarsus XR C max c (ng/mL) T max d (hr) AUC 24 c (ng•hr/mL) C 24 h (ng/mL) Healthy Subjects a (n=19) 2 mg 2 mg Day 1 Day 10 11.9 3.8 8.3 2.9 14.0 [6 - 28] 8.0 [1.0-12.0] 50 14 140 50 1.8 0.6 4.6 1.7 Adult Kidney a De novo e (n=21) 11.8 mg f 10 mg 9.5 mg Day 1 Day 7 Day 14 11.8 7.2 25.1 16.3 27.1 13.4 8.0 [4-24] 6.0 [2-12] 4.0 [1-8] 138 80 335 129 371 104 5.2 2.7 9.9 4.4 11.4 4.1 j Adult Kidney a De novo (n=10) 15.5 mg g 11.4 mg 11.1 mg Day 1 Day 14 Day 28 33.6 21.8 31.1 14.6 35.9 18.7 6.0 [4-24] 4.0 [1-18] 4.0 [1-14] 377 257 376 140 396 150 11.0 6.1 9.1 3.0 10.5 3.2 Adult Kidney a (≥ 6 months post- transplant) (n=47) 5.3 mg Day 7 i 13.5 4.8 6.0 [1 - 16] 216 63 7.0 2.3 j Adult African- American Kidney k (≥ 6 months post-transplant) (n=46) 7.8 mg Day 7 i 18.4 7.2 5.0 [1 - 16] 272 97 7.8 2.9 j In adult kidney transplant patients ≥ 6 months post-transplant switched to Envarsus XR at 67% to 80% of the daily dose of tacrolimus immediate-release capsules component the steady state tacrolimus exposures (AUC 24 ) and tacrolimus trough concentrations (C 24 ) were comparable to the AUC 24 and C 24 measured prior to the switch. However habit
without warning ic Parameters of Envarsus XR C max c (ng/mL) T max d (hr) AUC 24 c (ng•hr/mL) C 24 h (ng/mL) Healthy Subjects a (n=19) 2 mg 2 mg Day 1 Day 10 11.9 3.8 8.3 2.9 14.0 [6 - 28] 8.0 [1.0-12.0] 50 14 140 50 1.8 0.6 4.6 1.7 Adult Kidney a De novo e (n=21) 11.8 mg f 10 mg 9.5 mg Day 1 Day 7 Day 14 11.8 7.2 25.1 16.3 27.1 13.4 8.0 [4-24] 6.0 [2-12] 4.0 [1-8] 138 80 335 129 371 104 5.2 2.7 9.9 4.4 11.4 4.1 j Adult Kidney a De novo (n=10) 15.5 mg g 11.4 mg 11.1 mg Day 1 Day 14 Day 28 33.6 21.8 31.1 14.6 35.9 18.7 6.0 [4-24] 4.0 [1-18] 4.0 [1-14] 377 257 376 140 396 150 11.0 6.1 9.1 3.0 10.5 3.2 Adult Kidney a (≥ 6 months post- transplant) (n=47) 5.3 mg Day 7 i 13.5 4.8 6.0 [1 - 16] 216 63 7.0 2.3 j Adult African- American Kidney k (≥ 6 months post-transplant) (n=46) 7.8 mg Day 7 i 18.4 7.2 5.0 [1 - 16] 272 97 7.8 2.9 j In adult kidney transplant patients ≥ 6 months post-transplant switched to Envarsus XR at 67% to 80% of the daily dose of tacrolimus immediate-release capsules you need to be
EmoticonEmoticon